
Ramon Salazar
@ramonsalazars
Medical Oncologist focused on GI cancer. Interested in new drug development, biomarker discovery & validation. Opinions are mine
ID: 273623356
28-03-2011 21:10:39
1,1K Tweet
1,1K Followers
483 Following


we are presenting the results of the multivariate analysis of the Grupo GETNE international phase 3 clinical trial SEQTOR at the ESMO 2024# congress, which starts tomorrow. Read more about it on the Cancer Musings Blog... prognostictools.es/blog/cancer-mu… prognostictools.es/blog/cancer-mu…

we are presenting the results of the multivariate analysis of the Grupo GETNE international phase 3 clinical trial SEQTOR at the #ESMO 2024 congress, which starts tomorrow. Read more about it on the Cancer Musings Blog... prognostictools.es/blog/cancer-mu… prognostictools.es/blog/cancer-mu…

El próximo lunes lunes presentamos los resultados del análisis multivariado del ensayo clínico fase 3 internacional SEQTOR del Grupo GETNE en el congreso #ESMO 2024 que empieza mañana. Os lo cuento en el Blog de Cancer Musings... prognostictools.es/blog/cancer-mu… prognostictools.es/blog/cancer-mu…

congrats to my colleagues at Institut Català d'Oncologia for their great effort and contribution to the #ESMO24 Congress. And again congrats my Grupo GETNE co-PIs for the great effort with #SEQTOR trial. Also great gratitude to all the patients involved who are the real stars

Prime Time para Grupo GETNE con Ramon Salazar presentando la última actualización del estudio SEQTOR en #ESMO24 ‼️ La quimioterapia con STZ/5FU mejora las opciones de respuesta tumoral en pacientes con tumores G2 🔥🔥🔥







Not all Liver Metastases from colorectal cancer are born equal, here is my commentary to an excellent paper of Dr. David Garcia Molleví from Institut Català d'Oncologia IDIBELL , with very interesting potential insights for personalized inmune therapies prognostictools.es/blog/cancer-mu…







